Leonid Heifets

7.8k total citations · 1 hit paper
98 papers, 5.7k citations indexed

About

Leonid Heifets is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Leonid Heifets has authored 98 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Epidemiology, 76 papers in Infectious Diseases and 22 papers in Molecular Biology. Recurrent topics in Leonid Heifets's work include Tuberculosis Research and Epidemiology (73 papers), Mycobacterium research and diagnosis (71 papers) and Quinazolinone synthesis and applications (13 papers). Leonid Heifets is often cited by papers focused on Tuberculosis Research and Epidemiology (73 papers), Mycobacterium research and diagnosis (71 papers) and Quinazolinone synthesis and applications (13 papers). Leonid Heifets collaborates with scholars based in United States, Netherlands and United Kingdom. Leonid Heifets's co-authors include Pamela J. Lindholm-Levy, Kevin O. Kisich, Michael D. Iseman, Svetlana Gelperina, N Mor, Michael H. Cynamon, M D Iseman, Max Salfinger, Michael Higgins and Charles L. Daley and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Leonid Heifets

97 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis

2005 543 citations Svetlana Gelperina, Kevin O. Kisich et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leonid Heifets United States	44	3.8k	3.8k	1.2k	836	575	98	5.7k
Giovanni Fadda Italy	47	3.6k 0.9×	3.9k 1.0×	1.2k 1.0×	858 1.0×	1.3k 2.2×	137	7.1k
George A. Pankey United States	33	2.5k 0.7×	2.9k 0.8×	636 0.5×	503 0.6×	788 1.4×	115	5.7k
Michael H. Cynamon United States	41	2.9k 0.8×	2.5k 0.7×	1.5k 1.3×	553 0.7×	573 1.0×	132	4.8k
Jeffrey J. Tarrand United States	44	3.0k 0.8×	3.6k 0.9×	974 0.8×	415 0.5×	362 0.6×	135	6.6k
Vincent T. Andriole United States	40	1.8k 0.5×	2.7k 0.7×	567 0.5×	551 0.7×	502 0.9×	144	5.1k
Emmanuelle Cambau France	46	4.5k 1.2×	5.0k 1.3×	2.2k 1.9×	1.3k 1.6×	1.7k 2.9×	148	8.3k
Sung Jae Shin South Korea	45	3.9k 1.0×	4.5k 1.2×	1.4k 1.2×	679 0.8×	297 0.5×	276	7.0k
Béate Heym France	32	3.1k 0.8×	3.1k 0.8×	1.2k 1.0×	1.0k 1.2×	801 1.4×	79	4.6k
Yoshitsugu Miyazaki Japan	40	2.5k 0.7×	2.7k 0.7×	1.3k 1.2×	291 0.3×	499 0.9×	323	5.9k
Lowell S. Young United States	39	2.0k 0.5×	2.8k 0.8×	616 0.5×	370 0.4×	966 1.7×	123	6.8k

Countries citing papers authored by Leonid Heifets

Since Specialization

Citations

This map shows the geographic impact of Leonid Heifets's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonid Heifets with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonid Heifets more than expected).

Fields of papers citing papers by Leonid Heifets

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonid Heifets. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonid Heifets. The network helps show where Leonid Heifets may publish in the future.

Co-authorship network of co-authors of Leonid Heifets

This figure shows the co-authorship network connecting the top 25 collaborators of Leonid Heifets. A scholar is included among the top collaborators of Leonid Heifets based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonid Heifets. Leonid Heifets is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Ingen, Jakko van, Eric F. Egelund, Adrah Levin, et al.. (2012). The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment. American Journal of Respiratory and Critical Care Medicine. 186(6). 559–565. 146 indexed citations

2.

Ingen, Jakko van, Martin J. Boeree, Dick van Soolingen, et al.. (2011). Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?. Infection Genetics and Evolution. 12(4). 832–837. 26 indexed citations

3.

Chung, Woo Jin, Andrei Kornilov, Benjamin H. Brodsky, et al.. (2008). Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs. Tuberculosis. 88(5). 410–419. 14 indexed citations

4.

Kisich, Kevin O., Svetlana Gelperina, Michael Higgins, et al.. (2007). Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. International Journal of Pharmaceutics. 345(1-2). 154–162. 101 indexed citations

5.

Morris, Rowan P., Liem Nguyen, John Gatfield, et al.. (2005). Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences. 102(34). 12200–12205. 248 indexed citations

6.

Gelperina, Svetlana, Kevin O. Kisich, Michael D. Iseman, & Leonid Heifets. (2005). The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 172(12). 1487–1490. 543 indexed citations breakdown →

7.

Fennelly, Kevin P., et al.. (2003). Cough-generated Aerosols of Mycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine. 169(5). 604–609. 245 indexed citations

8.

Smith, Debra S., Pamela J. Lindholm-Levy, Gwen A. Huitt, Leonid Heifets, & James L. Cook. (2000). Mycobacterium terrae: Case Reports, Literature Review, and In Vitro Antibiotic Susceptibility Testing. Clinical Infectious Diseases. 30(3). 444–453. 58 indexed citations

9.

Benson, Constance A., Paige L. Williams, David L. Cohn, et al.. (2000). Clarithromycin or Rifabutin Alone or in Combination for Primary Prophylaxis ofMycobacterium aviumComplex Disease in Patients with AIDS: A Randomized, Double‐Blind, Placebo‐Controlled Trial. The Journal of Infectious Diseases. 181(4). 1289–1297. 62 indexed citations

10.

Cohn, David L., Evelyn J. Fisher, James S. Hodges, et al.. (1999). A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients. 67. 1 indexed citations

11.

Cohn, David L., Evelyn J. Fisher, James S. Hodges, et al.. (1999). A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin. 67. 520–521. 1 indexed citations

12.

Cohn, David L., Evelyn J. Fisher, Grace Peng, et al.. (1999). Prospective Randomized Trial of Four Three‐Drug Regimens in the Treatment of DisseminatedMycobacterium aviumComplex Disease in AIDS Patients: Excess Mortality Associated with High‐Dose Clarithromycin. Clinical Infectious Diseases. 29(1). 125–133. 43 indexed citations

13.

Oldfield, Edward C., W. Jeffrey Fessel, Michael W. Dunne, et al.. (1998). Once Weekly Azithromycin Therapy for Prevention ofMycobacterium aviumComplex Infection in Patients with AIDS: A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Trial. Clinical Infectious Diseases. 26(3). 611–619. 59 indexed citations

14.

Hafner, Richard, David J. Wright, Nancy E. Dunlap, et al.. (1997). Early Bactericidal Activity of Isoniazid in Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 156(3). 918–923. 34 indexed citations

15.

Heifets, Leonid, et al.. (1994). Quantitation of mycobacteria in blood specimens from patients with AIDS. PubMed. 75(5). 386–390. 11 indexed citations

16.

Gordon, Steven, C. Robert Horsburgh, Charles A. Peloquin, et al.. (1993). Low Serum Levels of Oral Antimycobacterial Agents in Patients with Disseminated Mycobacterium avium Complex Disease. The Journal of Infectious Diseases. 168(6). 1559–1562. 54 indexed citations

17.

Shih, Jen-Fu, et al.. (1989). Minimal Inhibitory Concentrations of Rifabutin, Ciprofloxacin, and Ofloxacin against Mycobacterium tuberculosis Isolated before Treatment of Patients in Taiwan. American Review of Respiratory Disease. 140(4). 987–989. 25 indexed citations

18.

Lindholm-Levy, Pamela J. & Leonid Heifets. (1988). Clofazimine and other rimino-compounds: Minimal inhibitory and minimal bactericidal concentrations at different pHs for mycobacterium avium complex. Tubercle. 69(3). 179–186. 30 indexed citations

19.

Lin, Tao, et al.. (1988). Minimal Inhibitory Concentrations of Isoniazid, Rifampin, Ethambutol, and Streptomycin against Mycobacterium tuberculosis Strains Isolated before Treatment of Patients in Taiwan. American Review of Respiratory Disease. 138(4). 999–1001. 23 indexed citations

20.

Heifets, Leonid & Pamela J. Lindholm-Levy. (1987). Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against mycobacterium tuberculosis and mycobacterium avium complex. Tubercle. 68(4). 267–276. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact